Overview

Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer

Status:
Completed
Trial end date:
2000-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have metastatic or recurrent breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborator:
National Cancer Institute (NCI)
Treatments:
Camptothecin
Irinotecan